References
Beste LA, Leipertz SL, Green PK, Dominitz JA, Ross D, Ioannou GN. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001–2013. Gastroenterology. 2015;149:1471-82.e5. https://doi.org/10.1053/j.gastro.2015.07.056.
Mittal S, Sada YH, El-Serag HB, et al. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol. 2015. https://doi.org/10.1016/j.cgh.2014.08.013.
Polanco PM, Ju MR, Chansard M, et al. Trends and disparities in treatment utilization for early-stage hepatocellular carcinoma in the veteran population. Ann Surg Oncol. 2022. https://doi.org/10.1245/s10434-022-11897-3
Zhang X, El-Serag HB, Thrift AP. Predictors of five-year survival among patients with hepatocellular carcinoma in the United States: an analysis of SEER-Medicare. Cancer Causes Control. 2021;32:317–25. https://doi.org/10.1007/s10552-020-01386-x.
Davila JA, Kramer JR, Duan Z, et al. Referral and receipt of treatment for hepatocellular carcinoma in United States veterans: effect of patient and nonpatient factors. Hepatology. 2013;57:1858–68. https://doi.org/10.1002/hep.26287.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Disclosures
There are no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Ju, M.R., Polanco, P.M. ASO Author Reflections: Disparities in Utilization of Curative-Intent Therapy for Veterans with Early-Stage HCC. Ann Surg Oncol 29, 5498–5499 (2022). https://doi.org/10.1245/s10434-022-11956-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1245/s10434-022-11956-9